+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 9 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.

Age: 18Years +All GendersPhase 3
563 locations
E

Actively Recruiting

Researchers are evaluating how well LY3537021 works and how safe it is for controlling nausea and vomiting caused by chemotherapy in adults with cancer. This phase 2 study compares LY3537021 with a placebo, both given along with standard anti-nausea medicines. The study focuses on adults who have not previously received chemotherapy and are planned to receive specific types of chemotherapy drugs. Participants receive either LY3537021 or placebo as a subcutaneous injection before chemotherapy, along with standard antiemetic treatments taken by mouth, intravenously, or through skin patches, depending on local guidelines. The chemotherapy drugs used include cisplatin or anthracycline with cyclophosphamide administered intravenously. The study uses a double-blind and randomized design to compare the two groups. Throughout the study, participants are monitored for nausea and vomiting during the period from the start of chemotherapy through 120 hours after the first infusion. Researchers assess the proportion of participants who have a complete response, meaning no vomiting and no need for additional rescue medication, particularly in the delayed phase. Participants remain in the study for about two months until all parts are completed, including safety evaluations and pharmacokinetic measurements.

Age: 18Years +All GendersPhase 2
67 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of Hetrombopag Olamine Tablets compared to a placebo in patients with thrombocytopenia caused by chemotherapy. The study focuses on patients who have solid tumors and experience low platelet counts due to chemotherapy treatment. This phase III trial is conducted by Jiangsu HengRui Medicine Co., Ltd. and aims to better understand treatment options for chemotherapy-induced thrombocytopenia. Participants receive treatments in two parts in Part A, all participants are given Hetrombopag Olamine. In Part B, participants are randomly assigned to receive either Hetrombopag Olamine or a matching placebo. Treatments are given during chemotherapy cycles that occur every 14 or 21 days. The study includes monitoring over approximately 3 years to assess platelet counts and the need for rescue therapies. During the study, participants undergo regular monitoring of platelet levels, safety labs, and vital signs. Researchers track whether participants maintain platelet counts sufficient to continue chemotherapy without delay or modification. Outcomes include measuring platelet count improvements, bleeding events, and adverse reactions. The overall participation lasts up to about three years, with ongoing assessment of chemotherapy cycle completion and treatment safety.

Age: 18Years +All GendersPhase 3
51 locations
S

Actively Recruiting

Cervical radiculopathy is a condition caused by irritation or compression of cervical nerve roots, often resulting in one-sided neuropathic pain and difficulty with arm movement. This study aims to evaluate how an interlaminar epidural steroid injection ILESI affects upper arm proprioception, or the sense of joint position, in patients with chronic cervical radiculopathy due to cervical disc herniation. The study also explores how changes in proprioception relate to symptoms like pain, disability, grip strength, and quality of life. Participants will receive a single standardized ILESI at the C7-T1 level using fluoroscopic guidance. The injection includes a mixture of corticosteroid, local anesthetic, and saline. Evaluations will be done at three times before the injection, three weeks after, and three months after. The study uses a validated joint position sense test called PRO-Reach to assess proprioception and measures other clinical outcomes such as neuropathic pain scores, pain intensity, disability, hand-grip strength, and quality of life. During the study, participants will undergo tests and questionnaires at each visit to assess their symptoms and function. Data will be collected by blinded assessors to reduce bias. The main outcome is the change in upper extremity proprioception error over time. Secondary outcomes include changes in neuropathic pain, pain intensity, disability, grip strength, and quality of life. The study will last for at least three months of follow-up, with careful monitoring of participants progress and safety.

Age: 18Years - 65YearsAll GendersPhase Not Applicable
1 location
S

Actively Recruiting

Lumbar spinal stenosis is a condition where the spinal canal narrows due to degenerative changes in the joints, discs, and ligamentum flavum, causing symptoms like neurogenic claudication, leg pain, low back pain, and sometimes urinary or fecal incontinence. This research aims to explore if the presence of spinal dural pulsation, a rhythmic movement of the dura mater seen in imaging, is linked to clinical symptoms and radiological findings in people diagnosed with lumbar spinal stenosis. Participants will be assessed for the presence of dural pulsation using ultrasound while lying face down. The study groups include those positive for dural pulsation and those negative for it. Magnetic Resonance Imaging MRI will also be used to measure spinal canal features such as dural diameter and cross-sectional area at affected levels. The study correlates these findings with clinical symptoms and disability scores. During the study, participants will undergo evaluations including pain rating scales, disability indexes, quality of life questionnaires, and walking capacity tests. MRI scans will assess anatomical features related to stenosis. These assessments occur at the time of data collection to understand the relationship between dural pulsation and patient symptoms. The study excludes individuals with certain conditions like prior lumbar surgery or inflammatory diseases and plans to complete by the end of 2026.

Age: 18Years - 85YearsAll Genders
1 location
E

Actively Recruiting

This clinical trial studies seladelpar, a drug being evaluated for its effects on people with primary biliary cholangitis PBC who have compensated cirrhosis. The main goal is to compare seladelpar with a placebo to see how it impacts event-free survival EFS, which measures the time until certain liver-related events occur over a period of up to 156 weeks. This research is led by Gilead Sciences and takes place in a phase 3 setting, aiming to better understand treatment outcomes for PBC patients with cirrhosis. Participants with Child-Pugh class A cirrhosis will receive 10 mg of seladelpar orally once daily, while those with Child-Pugh class B will receive 5 mg once daily, both for up to 36 months. Another group with either Child-Pugh class A or B will receive a placebo matching the study drug daily for the same duration. After 156 weeks, participants with Child-Pugh class A or B who remain on the study drug may continue seladelpar at the respective doses for an additional maximum of 3 years during an open-label extension phase. Participants will be monitored throughout the study with regular assessments to evaluate liver function and clinical events related to PBC and cirrhosis. Researchers will measure outcomes such as event-free survival, overall survival, time to hospitalization, and liver transplant-free survival. Safety and liver health will be closely followed using laboratory tests and imaging. The total participation time may extend up to several years, depending on continued study drug use and follow-up requirements.

Age: 18Years +All GendersPhase 3
218 locations
P

Actively Recruiting

Researchers are evaluating the combination of izalontamab brengitecan Iza-bren with osimertinib compared to osimertinib alone or osimertinib combined with platinum-based chemotherapy for participants with previously untreated, locally advanced or metastatic EGFR-mutant non-small cell lung cancer NSCLC. This Phase III randomized study aims to assess these treatments as first-line therapy in this patient population. Participants will receive one of the study treatments Iza-bren combined with osimertinib, osimertinib alone, or osimertinib combined with platinum-based chemotherapy including drugs such as pemetrexed, carboplatin, or cisplatin. Drug doses are specified on certain days, and treatment continues as per protocol. The study design is parallel and open-label with random assignment to one of the treatment arms. During the study, participants will be monitored through assessments including progression-free survival measured by blinded independent central review and investigator evaluation up to approximately three years. Additional evaluations include overall survival, objective response rates, disease control rates, and duration of response measured up to about five years. Safety and treatment effects will be closely observed throughout the study period which may last several years.

Age: 18Years +All GendersPhase 3
204 locations
E

Actively Recruiting

Researchers are evaluating whether olomorasib combined with immunotherapy is more effective than standard immunotherapy alone for people with KRAS G12C-mutant non-small cell lung cancer NSCLC. The study has two parts Part A focuses on participants with resected NSCLC treated with pembrolizumab, and Part B includes participants with unresectable NSCLC treated with durvalumab. This Phase 3 study aims to assess disease control and survival outcomes over several years. Participants will be randomly assigned to receive either olomorasib or a placebo, both given orally, combined with intravenous pembrolizumab or durvalumab depending on the study part. Treatment with the combination lasts for up to 1 year, followed by olomorasib or placebo alone for up to 3 years. The study involves parallel groups comparing these combinations in participants with either resected or unresectable disease. During the study, participants will have regular assessments including disease monitoring for progression or recurrence, quality of life questionnaires, and evaluations of lung cancer symptoms. Researchers will track outcomes such as disease-free survival in Part A and progression-free survival in Part B, along with overall survival and symptom changes. The total participation may last about 3 years, with ongoing follow-up to monitor safety and treatment effects.

Age: 18Years +All GendersPhase 3
368 locations
P

Actively Recruiting

Researchers are examining the effect of abelacimab compared to a placebo in patients with atrial fibrillation AF who are considered unsuitable for oral anticoagulation therapy. This Phase 3 study focuses on high-risk patients with AF to evaluate whether abelacimab can reduce the occurrence of ischemic stroke or systemic embolism. The study is led by Anthos Therapeutics, Inc. and aims to address treatment options in patients where traditional anticoagulation is deemed inappropriate. Participants are randomly assigned in equal numbers to receive either abelacimab 150 mg or a matching placebo by subcutaneous injection once a month. The study consists of three periods a screening period lasting up to 60 days, a double-blind treatment period that continues until at least 111 patients experience a primary endpoint event, and an end-of-treatment visit. Following this, participants may enter a 30-day follow-up or an optional open-label extension to receive abelacimab, depending on eligibility and regulatory approval. During the study, participants undergo assessments to monitor stroke, systemic embolism, and bleeding events, with the primary outcomes measured up to 30 months. Safety is tracked by recording bleeding events classified by the Bleeding Academic Research Consortium. Secondary outcomes include cardiovascular and all-cause mortality and other thrombotic events. The study also involves regular monitoring and follow-up visits to assess efficacy and safety throughout the treatment and observation periods.

Age: 65Years +All GendersPhase 3
789 locations